ANIX — Anixa Biosciences Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 715446 ·
Last close
$3.06
Market Cap
$104.11M
52W High
$3.48
52W Low
$2.32
ADV30
244,528
Next earnings
2026-09-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -2,647,000 | -2,516,000 | 14,865,000 | 1,477,000 | 1,641,000 |
| Jan 2026 | 0 | — | -2,716,000 | -2,565,000 | 15,233,000 | 1,547,000 | 1,387,000 |
| Oct 2025 | 0 | — | -2,876,000 | -2,695,000 | 16,080,000 | 1,244,000 | 2,130,000 |
| Jul 2025 | 0 | — | -2,436,000 | -2,258,000 | 17,651,000 | 1,495,000 | 2,240,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,117,000
Investing CF
$1,471,000
Financing CF
$5,213,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-06-14
Balance + Analyst (yfinance extras)
Retained Earnings
$-256,758,000
Inventory
—
Receivables
$56,000
ST Investments
$12,209,000
EBIT TTM
$-10,675,000
Pretax Income TTM
$-10,123,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -11,701,000 | -10,927,000 | 16,080,000 | 2,130,000 | — | -7,173,000 |
| Oct 2024 | 0 | -13,831,000 | -12,554,000 | 21,591,000 | 2,703,000 | — | -7,335,000 |
| Oct 2023 | 210,000 | -11,011,000 | -9,811,000 | 25,522,000 | 2,151,000 | — | -6,209,000 |
| Oct 2022 | 0 | -13,875,000 | -13,595,000 | 30,412,000 | 2,212,000 | — | -6,492,000 |
| Oct 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.31
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.06 · call volume: 9 · put volume: 81
Expected Move to 2026-10-16:
±$1.77
(58.01%) —
implied range
$1.28 –
$4.83
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONCY | ONCOLYTICS BIOTECH INC | $105.90M | $0.89 | — |
| RVRC | Revium Rx. | $101.42M | $1.67 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $107.54M | $6.26 | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $109.19M | $6.28 | — |
| HSTC | HST Global, Inc. | $99.00M | $0.70 | — |
News headlines (Yahoo Finance, 1h cache)
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
2026-07-06 12:30 · Yahoo
Anixa Biosciences secures Korean patent for breast cancer vaccine
2026-06-30 10:31 · Yahoo
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
2026-06-29 12:45 · Yahoo
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontier
2026-06-26 13:10 · Yahoo
Here's Why You Should Add ANIX Stock to Your Portfolio Now
2026-06-25 14:30 · Yahoo
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
2026-06-11 13:05 · Yahoo
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
2026-06-01 13:00 · Yahoo
/C O R R E C T I O N -- Anixa Biosciences, Inc./
2026-05-11 15:48 · Yahoo
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
2026-05-01 13:15 · Yahoo
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
2026-04-29 13:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.